AGTC -4%, presumably in sympathy move with AAVL. This is silly, however, insofar as all of AGTC’s gene-therapy programs are in rare (monogenic) ophthalmic diseases.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.